Wellness Clinical Research is recognizing Principal Investigator Lucky Flores, MD, for his documented participation in a randomized Phase 2 study of mirikizumab in Crohn’s disease.
The Gastroenterology publication evaluated mirikizumab in patients with moderate-to-severe Crohn’s disease, and the study’s investigator supplement lists Lucky Flores with Wellness Clinical Research in Florida.
Phase 2 Crohn’s disease research
The study evaluated mirikizumab, an antibody targeting the p19 subunit of interleukin-23, in participants with moderate-to-severe Crohn’s disease.
The primary objective assessed endoscopic response at Week 12, with longer-term outcomes followed through Week 52.
Investigator documentation for Wellness Clinical Research
The publication’s investigator supplement identifies Lucky Flores with Wellness Clinical Research in Florida among the participating investigators.
That supplemental listing provides the public documentation connecting Dr. Flores and Wellness Clinical Research to the study, while the PubMed record provides the publication details and results.